Quick Takeaways
- ImmunoGen, Inc. has 20 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are not currently available.
- Info
- Insider Trading
- Financials
Insider Transactions Reported by 20 Insiders of ImmunoGen, Inc.
- Location
- Waltham, MA
What Changed
- No meaningful buy/sell imbalance is currently visible in the one-year window.
- Activity will update as new Forms 3/4/5 are filed.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsInsider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 13 Apr 2025.
Buys
$0
Shares: 0
Insiders: 0
Sells
$0
Shares: 0
Insiders: 0
Net
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
ImmunoGen, Inc. executives and other stock owners filed with the SEC include:
Top shareholders of ImmunoGen, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Anna Berkenblit |
3/4/5
|
SVP & CHIEF MEDICAL OFFICER |
—
class O/S missing
|
113,935
|
$3,377,033 | — | 30 Jun 2023 | |
| Thomas Ryll |
3/4/5
|
SVP, Technical Operations |
—
class O/S missing
|
84,714
|
$2,510,923 | — | 30 Jun 2021 | |
| Kristen Harrington-Smith |
3/4/5
|
SVP & CHIEF COMMERCIAL OFFICER |
—
mixed-class rows
|
75,000
mixed-class rows
|
$2,211,000 | — | 15 Nov 2022 | |
| Stacy Ann Coen |
3/4/5
|
SVP & CHIEF BUSINESS OFFICER | — | — | $1,383,800 | — | 12 Feb 2024 | |
| Mark J. Enyedy |
3/4/5
|
CHIEF EXECUTIVE OFFICER, Director | — | — | $897,750 | — | 12 Feb 2024 | |
| Susan Altschuller |
3/4/5
|
SVP AND CFO |
—
class O/S missing
|
123,750
|
$564,300 | — | 20 May 2022 | |
| Renee Lentini |
3/4/5
|
VP & PRIN ACCTG OFFICER | — | — | $245,469 | — | 12 Feb 2024 |
Recent Insider Transactions by Companies or Individuals for ImmunoGen, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* An asterisk sign (*) next to the price indicates that the price is likely invalid.